Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Hagop Kantarjian, Nicola Gökbuget et al.|Leukemia Research|2019Cited by 52
Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemiaShunsuke Kimura, Charles G. Mullighan, Claudia Haferlach et al.|Blood|2022Cited by 50
Indian Hedgehog release from TNF-activated renal epithelia drives local and remote organ fibrosisEoin O’Sullivan, David A. Ferenbach, Katie J. Mylonas et al.|Science Translational Medicine|2023Cited by 45